Neurocil (Citicoline)

Quick links

Choose a section

Quick links to important sections

Advertisements

Neurocil (Citicoline)

Advertisements
Advertisements

Treatment option: Cerebrovascular Accident

Advertisements

Overview of Neurocil (Citicoline)

Property Description
Active ingredient Citicoline (CDP-Choline)
Forms Oral solution, Tablets, Solution for injection
Pharmacological class Nootropic and Neuroprotective Agent
General Purpose Supports nerve cell structure and neurological function
Origin Synthetic derivative of an endogenous compound

The Identity and Classification of Neurocil (Citicoline)

Neurocil is a pharmaceutical preparation containing the active ingredient Citicoline, which is the International Nonproprietary Name (INN) for Cytidine Diphosphate-Choline or CDP-Choline. The substance is chemically identical to an essential endogenous intermediate that is naturally utilized by the body in cell metabolism. Citicoline is categorized within the Anatomical Therapeutic Chemical (ATC) Classification System as an other psychostimulant and nootropic (ATC Code N06BX06).

This classification is based on pharmacological properties that recognize its role in supporting neurological health. As a single-ingredient product, Neurocil's identity is defined by its focus on enhancing foundational brain metabolism, differentiating it from combination therapies.


Composition and Available Forms of Neurocil

The composition of Neurocil consists of the active substance Citicoline combined with either an aqueous vehicle for liquid formats or solid excipients for oral forms. The drug is available in several high-level dosage forms, including a solution for injection and forms intended for the oral route, such as tablets or an oral solution. This range of forms allows the medicine to be administered via both the parenteral (injection) and oral routes, defining the physical variants of the product without reference to specific strength or concentration.


Neurocil's General Purpose as a Neuroprotector

The broad purpose of Citicoline is centered on maintaining the structural integrity and metabolic activity of nerve cells. It functions as a necessary phosphatidylcholine precursor, supplying the molecular components required for the body to synthesize and repair neuronal membranes. This action is essential for helping the protective layers of brain cells stay healthy. The drug supports the body's ability to maintain cell function and sustain neurological communication, which is why it is used in situations requiring support for cognitive functions like memory and focus.

Advertisements

What side effects are possible with Neurocil (Citicoline)?

Possible Side Effects and Safety Information

The safety profile of Citicoline, as documented in official regulatory labeling, describes adverse reactions classified primarily by frequency and the body system affected. Regulatory documents categorize most listed effects as Uncommon, Very Rare, or of Not Known frequency, meaning that definitive incidence rates cannot be reliably estimated from the available data.

Adverse reactions are grouped into official System-Organ Classes (SOCs), with the most frequently mentioned effects concerning the Gastrointestinal System and the Nervous System.


Regulatory Classification of Adverse Reactions

The following high-level systems and reactions are documented in official prescribing information:

System-Organ Class Examples of Documented Adverse Reactions
Nervous System Disorders Headache, Dizziness, Insomnia, Excitation
Gastrointestinal Disorders Nausea, Vomiting, Diarrhea, Abdominal pain
Vascular Disorders Hypotension (low blood pressure), Tachycardia (fast heart rate)
Immune System Disorders Allergic reactions (e.g., rash, pruritus, urticaria)

Serious Adverse Reactions and Safety Constraints

Official documents specifically list Severe Hypersensitivity reactions (Allergies) and episodes of pronounced Hypotension as serious adverse reactions that require recognition.

Regulatory safety constraints advise against use in individuals with known Hypersensitivity to the active substance or excipients. Furthermore, the official label highlights a specific safety note regarding patients with Severe Vagotonia (a nervous system state often linked to a slowed heart rate), where administration may be restricted due to documented risk. A high-level safety caution is also noted for concurrent use with medicines containing Levodopa (L-Dopa), due to the potential for an additive safety consequence.

Advertisements

Overdose and Emergency Response

The official regulatory documents state that an overdose of Neurocil (Citicoline) may be associated with a range of documented clinical manifestations. These signs primarily involve the central nervous and cardiovascular systems. Neurological effects listed in the labeling include drowsiness, loss of consciousness, and the presence of severe extrapyramidal dyskinesias.

Cardiovascular findings associated with overdose include both hypotension and tachycardia. More serious physiological outcomes that may occur include life-threatening ventricular arrythmias and significant electrocardiogram (ECG) changes, along with systemic hypothermia.

The regulatory profile mandates patients to seek medical attention immediately upon the first sign of an overdose or any severe adverse drug reaction. Since the official prescribing information states that no specific antidote is known for Citicoline, the mandated treatment approach is defined as supportive treatment. Officially described procedural measures may include the administration of activated charcoal and the consideration of gastric lavage, particularly if the ingestion of a toxic dose occurred within approximately six hours of the medical observation.

Advertisements

Therapeutic Uses of Neurocil (Citicoline)

What Neurocil (Citicoline) Treats: Main Uses and Benefits

Neurocil (Citicoline) is commonly used to provide supportive therapeutic benefits within the neurological domain, aiming to ease the symptom burden across various conditions related to brain function and recovery. Citicoline is commonly used to help with conditions that present with disruptive symptom manifestations, such as those related to cognitive impairment, and is relevant in contexts involving heightened systemic burden following events like stroke and traumatic brain injuries (TBI).

The medication may assist with managing symptom clusters that may become intense or disruptive, including cognitive deficits (like chronic forgetfulness), attention deficits, and functional neurological impairment. It is often used during phases when symptoms become more noticeable, where supportive symptom management may be part of the care plan.

“Neurocil is relevant in contexts marked by increased discomfort and supports general well-being during symptomatic phases.”

The medication may help patients cope more steadily with symptom fluctuations, and contributes to improved day-to-day comfort during periods of heightened symptoms.

Quick Fact: Symptomatic support for Cognitive and Attention Deficits This medication may be part of symptomatic management that assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Neurocil (Citicoline) — Official Regulatory Information

Eligibility Scope

Population Group Regulatory Status
Adults and Older Adults Established for standard use; no dosage adjustment required for the elderly.
Hypersensitive Patients Contraindicated (Absolute Prohibition).
Hypertonia of Parasympathetic Contraindicated (Absolute Prohibition).
Children (Pediatric) Restricted/Conditional Use; experience is limited, only prescribed if benefits outweigh potential risks.
Pregnancy and Lactation Conditional Use; administration is limited to cases where the benefit clearly outweighs the potential risk to the fetus or baby.

Eligibility Classifications (High-Level)

  • Eligibility Severity Classification: The profile classifies non-eligibility as Contraindicated (Absolute Prohibition) and Conditional Use (Risk-Benefit Assessment Required).
  • Comorbidity-Linked Cautions: Caution is officially advised for patients with Parkinson's disease or in the presence of persistent intracranial bleeding.

Resulting Eligibility Structure

  • The medicine is formally contraindicated in patients with known hypersensitivity and in those with hypertonia of the parasympathetic nervous system.
  • Administration to children, and during pregnancy or lactation, is classified as conditional use, requiring regulatory risk-benefit justification.
  • Caution is required for patients with comorbidities like Parkinson's disease.

Connection to the overall eligibility profile:

Regulatory documents define eligibility by establishing absolute contraindications that prohibit use, alongside setting conditional-use requirements for populations with limited safety data, such as children and pregnant women. This structure ensures that use outside of the established adult population is formally restricted by a required risk-benefit assessment rather than a blanket approval.

Advertisements

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The regulatory profile for Citicoline identifies specific interactions that result in formal restrictions or modifications of effect. These interactions are strictly defined in government regulatory labeling and do not include pharmacokinetic interactions like CYP enzyme modulation or drug transporter effects.

Classification Interacting Substance Official Regulatory Statement
Contraindicated Combination Meclofenoxate (Clophenoxate) Must not be administered in conjunction with medicaments containing this substance.
Pharmacodynamic Potentiation L-dopa (Levodopa) Officially documented to potentiate or enhance the effects of L-dopa.
Substance Restriction Alcohol Should not be consumed while the preparation is in use.

This structure is characterized by a primary, formal prohibition against co-administration with Meclofenoxate, which represents the highest level of restriction. A specific pharmacodynamic interaction is documented with L-dopa, where Citicoline increases the resulting therapeutic effect of the co-administered drug. The profile also includes a mandatory substance restriction concerning the consumption of alcohol. No explicit administration timing rules or population-specific interaction cautions are noted in the official prescribing information.

Advertisements

Mechanism of Action

How Neurocil (Citicoline) Works

Neurocil (Citicoline) is a compound that works at the cellular level by engaging mechanisms that modulate neuronal signaling and influence biochemical processes within the central nervous system.


Phospholipid Synthesis and Membrane Integrity

Citicoline acts as a crucial precursor in the Kennedy pathway for the biosynthesis of structural phospholipids, primarily phosphatidylcholine . This mechanism contributes to the synthesis and structural stability of neuronal cell membranes, thereby influencing lipid dynamics within targeted pathways.


Modulation of Neurotransmitter Pathways

The compound modulates key pathways associated with chemical communication by acting as a source of choline for the synthesis of the neurotransmitter acetylcholine. Furthermore, it engages mechanisms that influence the levels of other key signaling molecules like dopamine and norepinephrine, altering the dynamics of neuronal signal transmission.


Cellular Neuroprotection and Redox Homeostasis

Citicoline initiates signaling sequences that influence mitochondrial integrity and attenuate the processes generating reactive oxygen species. This involves enhancing the synthesis of glutathione, which modulates the consequences of excessive free radical activity and influences cellular redox homeostasis.

Advertisements

Dosage and Administration Information

Neurocil (Citicoline) is administered according to prescribing guidelines which define the method, dose, and schedule for its use.

Official Administration Methods

The medication is available in multiple forms that determine its administration route:

  • Oral: Available as tablets (e.g., 500 mg or 1 g strengths) and oral solution, which can be taken with or without food. The oral solution may also be mixed with water for ingestion.
  • Parenteral: The medicine is available as a solution for injection for administration via the Intramuscular (IM) or Intravenous (IV) routes.

Standard Dosage and Frequency

Citicoline dosing is typically individualized by a healthcare professional. General dosing parameters define the adult daily dose range between 500 mg and 2000 mg (2 g) per day. The total daily dose is commonly divided for administration once or twice per day.

Procedural and Population-Specific Rules

Specific technical instructions apply to injectable forms and certain populations:

  • IV Injection: Direct intravenous injection is administered very slowly, usually over a period of 3 to 5 minutes.
  • Older Adults: Dose adjustment is generally not required for older adults.
  • Prohibited Co-administration: Citicoline must not be administered in conjunction with preparations that contain meclofenoxate.

Note: The total duration of use is typically determined by the clinical severity of the condition, as adjusted by the prescribing physician.

Advertisements

Recent Clinical Evidence

Neurocil (Citicoline): Recent Clinical Evidence

Neurocil (Citicoline) was studied in research contexts involving conditions characterized by systemic or functional imbalance within the neurological domain. The research base involves various controlled clinical trials and analyses that explored changes in function and symptom patterns over defined time intervals. This section focuses on the structure of the evidence, describing what was observed and where uncertainty remains, and does not provide clinical guidance or make claims about individual outcomes.


Evidence in the Context of Acute Neurological Injury

Research that was evaluated in patients who have recently experienced conditions such as acute ischemic stroke included large-scale Randomized Controlled Trials (RCTs). These studies typically conducted during periods of increased symptom activity and were defined by short-term evaluation periods, often 90 days. Researchers primarily monitored outcomes reflecting daily functioning or activity level, using standardized scales. The major RCTs reported mixed findings concerning the functional measurements at the primary assessment point. Subsequent data analyses described patterns observed in the studies related to the specific severity of the stroke, with some sub-group findings showing patterns when compared to the overall study population.


Evidence for Cognitive and Age-Related Deficits

Research examined Citicoline's use in patients with conditions marked by functional limitations, such as age-associated memory complaints and vascular cognitive impairment. This evidence base is generally comprised of smaller Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies focused on monitoring physiological strain or stress and measuring changes in specific cognitive domains, including memory, attention, and executive function. Research highlights changes measured in specific cognitive scores over defined time intervals. However, evidence quality varies across studies, and many of the reported outcomes were based on primary studies that frequently utilized small sample sizes and included heterogeneous groups of patients. Data for extended outcomes beyond the typical 6-month trial duration remain insufficient.


What is Still Uncertain in the Research

The overall body of evidence includes instances where findings were mixed across different populations or measured outcomes. There is a general lack of information regarding long-term outcomes that persist beyond the typical 3-to-6-month follow-up durations. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Anatomical Therapeutic Chemical (ATC) Classification System - Citicoline (N06BX06)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Neurocil (Citicoline) (FAQ)


Q: Are there any major food restrictions while taking Neurocil?

A: According to the official product information, Neurocil may be taken with or without food. There are no specific food restrictions mentioned in the regulatory profile beyond this instruction. This information is intended as a general summary; specific instructions from a healthcare professional should always be followed.


Q: Is Neurocil addictive?

A: Regulatory profiles classify Neurocil (Citicoline) as a nootropic or CNS agent. Official labeling does not contain any warnings related to abuse, addiction, or dependence. This suggests that the substance is not formally classified by regulators as carrying an addiction risk.


Q: Should Neurocil be taken in the morning or evening?

A: Regulatory documents indicate that the total daily dose is commonly divided for administration once or twice per day. While no mandatory time (morning or evening) is specified, the medication is generally intended to be taken at a consistent time as advised by a healthcare professional.


Q: Does Neurocil need a prescription in my country?

A: Regulatory labeling often includes warnings that this medication is not to be sold by retail without the prescription of a registered medical prescriber. This indicates that Neurocil is typically classified as a prescription-only medicine (POM) based on national drug authority listings.


Q: What is the difference between Neurocil and other choline supplements?

A: Official regulatory classification identifies Citicoline as an Active Pharmaceutical Ingredient (API) and a psychostimulant and nootropic agent. This pharmaceutical classification distinguishes it from products marketed as nutritional or dietary supplements, as its use is defined by regulatory bodies for medical purposes.


Q: Are there any warnings about Neurocil and driving or operating machinery?

A: Official safety warnings advise patients to exercise caution while driving or operating heavy machinery. This caution is due to the potential for documented side effects, such as dizziness or blurred vision, which may temporarily affect the ability to perform these tasks safely.


Q: Is there a maximum time frame for taking Neurocil?

A: Some research noted in official documents has established safety data for up to 12 months of continuous use. However, the total duration of treatment with Neurocil is typically determined individually based on the clinical severity of the condition and the decision of the prescribing physician.


Q: How long does Neurocil stay in your system?

A: Pharmacokinetic data from regulatory sources state that Neurocil has a relatively slow elimination process. Only a small amount is recovered in urine and faeces, and its biological half-life is described by a second peak concentration occurring around 125 hours after administration.


Q: Is it safe to crush or open Neurocil capsules/tablets?

A: Regulatory patient information often advises the user to swallow the tablet whole and explicitly cautions against chewing or crushing it. This ensures the correct and intended release of the medication into the body.


Q: Why is Neurocil sometimes given as an injection?

A: Official regulatory forms include a solution for injection to allow for administration via the Intramuscular (IM) or Intravenous (IV) routes. This route of administration is typically utilized in clinical settings, often reserved for use in cases of acute neurological injury.


Q: Can Neurocil be taken on an empty stomach?

A: Yes, official patient information explicitly states that the medicine may be taken with or without food. This means taking it on an empty stomach is consistent with the general administration guidelines.


Q: Can Neurocil affect sleep patterns?

A: Yes, regulatory documents list effects such as Insomnia (difficulty in sleeping) and Excitation under the Nervous System Disorders category of adverse reactions. Any unexpected changes or concerns related to sleep patterns should be discussed with a healthcare provider.


Q: Can Neurocil be used for stroke recovery?

A: Clinical evidence summarized in regulatory documents indicates that the substance has been studied in patients with acute ischemic stroke. Research results have been monitored for their effect on functional evolution in these patients, but research findings describe group patterns, not guarantees of individual outcome.


Q: Can Neurocil be used by healthy people for 'brain support'?

A: Regulatory indications define the use of the medicine for specific conditions, typically neurological or cerebrovascular disorders. The official prescribing information is therefore structured for use in patients with these conditions and is not generally indicated for healthy individuals.


Q: Do studies show Neurocil is effective for Alzheimer's disease?

A: While some official labels mention Alzheimer's disease as a condition for which the drug has been used or studied, the broader evidence summary notes that the quality of evidence varies and studies often involve small sample sizes in the context of cognitive deficits.


Q: What is the evidence regarding Neurocil for vascular dementia?

A: The official research base includes studies that examined Citicoline's use in patients with vascular cognitive impairment (which includes vascular dementia). In these studies, researchers monitored for changes in specific cognitive domains, such as memory and attention.

Advertisements

How should Neurocil (Citicoline) be stored and disposed of?

How to Store and Dispose of Neurocil (Citicoline)

Official regulatory guidelines define specific conditions for storing and discarding Neurocil (Citicoline) to maintain product stability and ensure safety.

Requirement Type Official Instructions
Temperature & Protection Store at temperatures not exceeding 30 C (86°F), or 25 C for some forms, and protect from light. The oral solution must not freeze.
Container & Safety Must be stored in the original packaging and kept out of the sight and reach of children. The product must not be used after the expiry date.
Disposal Do not throw away via wastewater or household waste. Patients must ask their pharmacist how to properly discard unused or expired medicine in compliance with applicable local regulations.

These instructions ensure that the medicine remains stable until its expiration date and that its disposal adheres to established pharmaceutical waste standards.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neurocil (Citicoline) found in:

A-Z Index: